RAMAT-GAN, Israel, June 15, 2015 /PRNewswire/ — Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company’s orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication. […]

BEDMINSTER, N.J., June 15, 2015 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa® (icosapent ethyl) in reducing lipids, triglycerides, apolipoproteins and PCSK9 […]

VIENNA, June 15, 2015 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted […]

TOKYO, June 15, 2015 /PRNewswire/ — Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries. Taiho Pharmaceutical Co., Ltd. retains the right […]

PHILADELPHIA, June 15, 2015 /PRNewswire/ — Today, as thousands of drug makers interact at the 2015 BIO International Convention, Deloitte is releasing a report suggesting that biopharmaceutical companies could have greater success if they collaborate with other organizations – even competitors – as part of an open innovation approach to research and development. The report – […]

Medivir AB (MVRBF), headquartered in Stockholm, Sweden, announced today that it will restructure its Discovery Research department, narrowing its focus to oncology and infectious diseases. In addition, it announced a partnership with gvk bioSciences Private Limited, located in Hyderabad, India. The partnership is designed with the expectation that it will improve quality and efficiency. It […]

Avalanche Biotechnologies Inc said its experimental eye drug met the main goal of a mid-stage study, sending its shares up about 16 percent after the bell. The drug, AVA-101, was effective in improving vision, compared with a placebo, in patients with wet age-related macular degeneration (AMD) – a disease affecting the retina of the eye, […]

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca (NYSE: AZN) today presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated […]

VIENNA & CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced long-term follow up of two patients with beta-thalassemia major and early safety and efficacy data in the first patient with severe sickle cell disease (SCD) […]

Investors who are champing at the bit for new data on Eli Lilly and Company (LLY)’s Alzheimer’s drug solanezumab have sent shares of the company up more than 10 percent this week, ahead of a disclosure at the Alzheimer’s Association International Conference (AAIC) expected by Monday. “If the drug works and is eventually approved, its […]